Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report

被引:168
|
作者
Drossman, Douglas A. [1 ]
Chang, L. [2 ]
Bellamy, N. [3 ]
Gallo-Torres, H. E. [4 ]
Lembo, A. [5 ]
Mearin, F. [6 ]
Norton, N. J. [7 ]
Whorwell, P. [8 ]
机构
[1] UNC Ctr Funct GI & Motil Disorders, Chapel Hill, NC 27599 USA
[2] UCLA Ctr Neurobiol Stress, Los Angeles, CA USA
[3] Univ Queensland, Ctr Natl Res Disabil & Rehabil Med, Brisbane, Qld, Australia
[4] US FDA, Div Gastrointestinal & Coagulat Drug Prod, Bethesda, MD 20014 USA
[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Cambridge, MA 02138 USA
[6] Ctr Med Teknon, Inst Funct & Motor Digest Disorders, Barcelona, Spain
[7] Int Fdn Funct Gastrointestinal Disorders, Milwaukee, WI USA
[8] Univ Manchester, Wythenshawe Hosp, Dept Gastroenterol, Manchester, Lancs, England
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2011年 / 106卷 / 10期
关键词
HEALTH-STATUS; ILLNESS SEVERITY; CONTROLLED-TRIAL; ABDOMINAL-PAIN; PRIMARY-CARE; IBS; SYMPTOMS; PREVALENCE; DISORDERS; MODERATE;
D O I
10.1038/ajg.2011.201
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: The concept of severity in irritable bowel syndrome (IBS) is clinically recognized and operative in diagnostic decision making and treatment planning. Yet, there is no consensus on its definition, and there are limited data on the prevalence of severity subgroups, its medical and psychosocial determinants, and its association with other health status measures. The aims of the Rome Foundation Working Team Committee were to summarize current research, to develop a consensus of understanding on this concept, and to make recommendations for its use in research and clinical care. METHODS: In 2006, a multinational committee of clinical investigators with expertise in IBS and/or psychometric research methods undertook a systematic review of the literature relating to severity in IBS. Owing to limited data, the Foundation commissioned three clinical studies to better characterize the concept of severity in IBS, and summary information and recommendations for future research and clinical care were developed. RESULTS: The main findings were: (i) severity in IBS is defined as a biopsychosocial composite of patient-reported gastrointestinal and extraintestinal symptoms, degree of disability, and illness-related perceptions and behaviors; (ii) both visceral and central nervous system physiological factors affect severity; as severity increases, the central nervous system provides a greater contribution; (iii) severity is related to and influences health-related quality of life and health behaviors and also guides diagnostic and therapeutic clinical decision making; (iv) severity can be subcategorized into clinically meaningful subgroups as mild (similar to 40 %), moderate (similar to 35 %), and severe (similar to 25 %), and this provides a working model for use in future research and clinical care. CONCLUSIONS: Future work is required to understand more precisely the factors contributing to severity and to develop a valid patient-reported instrument to measure severity in IBS.
引用
收藏
页码:1749 / 1759
页数:11
相关论文
共 50 条
  • [21] Splitting irritable bowel syndrome:: From original Rome to Rome II criteria
    Mearin, F
    Roset, M
    Badía, X
    Balboa, A
    Baró, E
    Ponce, J
    Díaz-Rubio, M
    Caldwell, E
    Cucala, M
    Fueyo, A
    Talley, NJ
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (01): : 122 - 130
  • [22] Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials
    Saps, M.
    van Tilburg, M. A. L.
    Lavigne, J. V.
    Miranda, A.
    Benninga, M. A.
    Taminiau, J. A.
    Di Lorenzo, C.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2016, 28 (11): : 1619 - 1631
  • [23] A survey of irritable bowel syndrome in vietnam using the rome criteria
    Zuckerman, Marc J.
    Nguyen, Giang
    Ho, Hoi
    Nguyen, Luat
    Gregory, Gavin G.
    DIGESTIVE DISEASES AND SCIENCES, 2006, 51 (05) : 946 - 951
  • [24] Irritable Bowel Syndrome: Straightening the road from the Rome criteria
    Camilleri, Michael
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32 (11):
  • [25] Alverine citrate, simeticone, and Rome III irritable bowel syndrome
    Ford, A. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (07) : 767 - 768
  • [26] A Survey of Irritable Bowel Syndrome in Vietnam Using the Rome Criteria
    Marc J. Zuckerman
    Giang Nguyen
    Hoi Ho
    Luat Nguyen
    Gavin G. Gregory
    Digestive Diseases and Sciences, 2006, 51 : 946 - 951
  • [27] Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV
    Stanghellini, Vincenzo
    DIGESTIVE DISEASES, 2017, 35 : 14 - 17
  • [28] The Rome criteria process: Diagnosis and legitimization of irritable bowel syndrome
    Drossman, DA
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10): : 2803 - 2807
  • [29] Rome Ⅲ survey of irritable bowel syndrome among ethnic Malays
    Yeong Yeh Lee
    Anuar Waid
    Huck Joo Tan
    Andrew Seng Boon Chua
    William E Whitehead
    World Journal of Gastroenterology, 2012, (44) : 6475 - 6480
  • [30] Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome
    Vanner, SJ
    Depew, WT
    Paterson, WG
    DaCosta, LR
    Groll, AG
    Simon, JB
    Djurfeldt, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10): : 2912 - 2917